1. Hale & Tempest Inhalation Drug Delivery Conference Dr. Brian W Tempest www.briantempest.com CpHI Ramada Hotel, Berlin, Germany 11 September 2013

2. Hale & Tempest Dr Brian Tempest advises Companies, Banks, High Net Worth Individuals and Investment Funds on their Strategy in the Emerging World based on his wide experience in China, Japan, South East Asia and India where he has lived for the last decade. Brian has worked for Ranbaxy Laboratories since 1995 holding the position of Managing Director and Chief Executive Officer until 2005. He was then Chief Mentor and Non Executive Director until 2008 when he retired. He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip MNC and as a result has a valuable insight into India. Brian has also worked for Glaxo as Regional Director Far East and Regional Director Middle East & Africa from 1985 to 1992. Brian has worked in the Pharmaceutical Industry for the last 41 years and has managed Healthcare businesses in North America, South America, Europe, Africa, Middle East, Australasia, China, Japan and India. He has also led many sessions at Investor Meetings held around the world. He is now Independent Chairman of Religare Capital Markets PLC, a Non Executive Director of Fortis Healthcare the leading Asian Healthcare Company, a Non Executive Director of SRL the largest Indian Diagnostic Company and a Non Executive Director of Glenmark Pharmaceuticals. He is a member of the SCRIP Global awards panel and is on the Editorial Board of the Journal of Generic Medicines. Brian speaks at global conferences and more information on these presentations can be found on his website www.briantempest.com. Brian has a PhD in Polymer Chemistry from Lancaster University in 1971 and in 2009 he became Chairman of the Advisory Board for the Lancaster University Management School, UK. He is a Fellow of the Royal Society of Medicine and a Fellow of the Royal Society of Chemistry and is a Chartered Chemist. He is now Chairman and Senior Partner of Hale & Tempest Co Ltd

3. Hale & Tempest There are only a few certain things Source: T Stevenson, Fidelity Worldwide Investment Director, S Telegraph April 21 2013 Populations growth Ageing Expansion of the World’s middle classes Increasing demand for healthcare is as close to given as investors can hope for

4. Hale & Tempest However forecasting can be difficult 2012 Nobel Laureate in Medicine - Biology School Report source: Daily Telegraph October 9 2012

5. Hale & Tempest Healthcare costs versus GDP & Wages

6. Hale & Tempest Everybody Concerned about Health Costs

7. Hale & Tempest OECD Healthcare Expenditure Growth source: Annalisa Belloni OECD at EGA Conference 13 June 2013

8. Hale & Tempest Euro Zone Express source: August 17 th 2013 The Economist

9. Hale & Tempest Public Health Reform Everywhere

10. Hale & Tempest Expanding Markets

11. Hale & Tempest A Slide from a UK Headhunter

12. Hale & Tempest R&D Productivity source: Evaluate Pharma 23 June 2013

13. Hale & Tempest Worldwide R&D Spend source: Evaluate Pharma 23 June 2013

14. Hale & Tempest Biosimilar Share to 2018 source: EvaluatePharma 2012

15. Hale & Tempest Biologics in 2016 Source: Cowen

16. Hale & Tempest Patent Cliff to 2018 source: Evaluate Pharma, Sandoz

17. Hale & Tempest Compounds Subject to Patent Challenge source: Thomson Reuters at 31 March 2013

18. Hale & Tempest Actavis R&D Assets source: Actavis Promotional Material before Warner Chilcott acquisition

19. Hale & Tempest Actavis Manufacturing Assets source: Actavis Promotional Material before Warner Chilcott acquisition

20. Hale & Tempest Global footprint of Watson/Actavis

21. Hale & Tempest Number of Companies with Active R&D Source: Citeline Pharmaprojects

22. Hale & Tempest Thank You brian.tempest@clara.co.uk www.briantempest.com